Who is sponsoring NCT04895514?

NCT04895514 is sponsored by Cornea and Laser Eye Institute.

What drugs are being tested in NCT04895514?

Interventions in NCT04895514: Gamma-irradiated corneal tissue inlay.

What condition does NCT04895514 study?

NCT04895514 studies Keratoconus.

Is NCT04895514 still recruiting?

NCT04895514 is currently status unknown. Last updated 14 November 2022.

Last reviewed 2022-11-14 · How we verify

NCT04895514

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gamma-Irradiated Corneal Inlay for Keratoconus

Status unknown NA Last updated 14 November 2022

What this trial tests

NA trial testing Gamma-irradiated corneal tissue inlay in Keratoconus in 10 participants. Status unknown.

Timeline

1 February 2021

Primary endpoint
1 June 2023

1 November 2023

Quick facts

Lead sponsor	Cornea and Laser Eye Institute
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 February 2021
Primary completion	1 June 2023
Estimated completion	1 November 2023
Sites	1 location across United States

Drugs / interventions tested

Gamma-irradiated corneal tissue inlay

Conditions studied

Keratoconus — all drugs for Keratoconus →

Sponsor

Cornea and Laser Eye Institute

Who can join

18 and older, any sex, with Keratoconus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study objective is to evaluate the outcomes of placing gamma-irradiated corneal tissue (VisionGraft, CorneaGen, USA) within the cornea of patients with keratoconus, a procedure called Corneal Tissue Addition for Keratoconus (CTAK).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Keratoconus

Currently open trials in the same condition.

NCT07372911 — PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus · NA · recruiting
NCT07461129 — Electrophysiological Changes in Cases of Different Stages of Keratoconus · active not recruiting
NCT06601101 — Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus · Phase 3 · recruiting
NCT05516004 — Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning · Phase 2 · recruiting
NCT06798779 — Predicting Manifest Astigmatism in Keratoconus Patients. · active not recruiting

Other Cornea and Laser Eye Institute trials

Trials by the same sponsor.

NCT04698590 — Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04895514 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cornea and Laser Eye Institute
Last refreshed: 14 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04895514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing